Javascript must be enabled to continue!
ANP and Bradycardic Reflexes in Hypertensive Rats
View through CrossRef
Abstract
—In previous studies we demonstrated that in normotensive rats, but not in spontaneously hypertensive rats (SHR), atrial natriuretic peptide (ANP) enhances bradycardic reflexes through an action on cardiac vagal afferent pathways. The present study aimed to determine whether cardiac hypertrophy, hypertension, or a nonreversible genetic factor accounted for the insensitivity of SHR to ANP action on cardiac reflex pathways. SHR were treated with the angiotensin-converting enzyme (ACE) inhibitor perindopril (3 mg/kg per day) for 6 weeks from 4 to 9 weeks of age (SHR-S, n=10) or for 9 weeks from 4 to 12 weeks of age (SHR-L, n=10) or were untreated (SHR, n=10) to produce differential effects on blood pressure and left ventricle/body weight ratio (LV/BW). Untreated normotensive Wistar-Kyoto rats (WKY, n=10) were also studied. At 13 weeks of age, all rats were instrumented with aortic and jugular catheters, and at 14 weeks we measured heart rate reflexes to rapid intravenous infusions of methoxamine (100 μg/kg, cardiac baroreflex) and serotonin (5 to 60 μg/kg, von Bezold-Jarisch cardiac chemosensitive reflex), with either α-rat ANP (150 ng/kg per minute IV) or saline vehicle (270 μL/h IV) infusion. Perindopril treatment for 6-week (SHR-S) and 9-week (SHR-L) durations maintained blood pressure at normotensive levels in both groups. SHR-S exhibited a small degree of cardiac hypertrophy (LV/BW was 8% higher than in WKY but 11% less than in untreated SHR), but LV/BW was normalized in SHR-L (to within 1% of WKY LV/BW). In WKY, ANP significantly (
P
<0.05) enhanced bradycardic responses to both the cardiac baroreflex (by 42±10%) and von Bezold-Jarisch chemosensitive reflex (by 17±5%) activation but had no effect in SHR. The cardiac reflex action of ANP was restored in SHR-L (ANP enhanced reflex bradycardia by 28±12% and 36±8%, baroreflex and von Bezold-Jarisch reflex, respectively;
P
<0.05), but SHR-S, which developed some cardiac hypertrophy, remained unresponsive to ANP. Our results suggest that the inability of ANP to sensitize cardiac vagal (nonarterial) afferents in SHR was not due to an inherited irreversible component, or the hypertension per se, but was associated with the presence of cardiac hypertrophy. A functional consequence of hypertension-induced cardiac hypertrophy may be the inhibition of the cardioprotective action of ANP through cardiac vagal reflexes.
Ovid Technologies (Wolters Kluwer Health)
Title: ANP and Bradycardic Reflexes in Hypertensive Rats
Description:
Abstract
—In previous studies we demonstrated that in normotensive rats, but not in spontaneously hypertensive rats (SHR), atrial natriuretic peptide (ANP) enhances bradycardic reflexes through an action on cardiac vagal afferent pathways.
The present study aimed to determine whether cardiac hypertrophy, hypertension, or a nonreversible genetic factor accounted for the insensitivity of SHR to ANP action on cardiac reflex pathways.
SHR were treated with the angiotensin-converting enzyme (ACE) inhibitor perindopril (3 mg/kg per day) for 6 weeks from 4 to 9 weeks of age (SHR-S, n=10) or for 9 weeks from 4 to 12 weeks of age (SHR-L, n=10) or were untreated (SHR, n=10) to produce differential effects on blood pressure and left ventricle/body weight ratio (LV/BW).
Untreated normotensive Wistar-Kyoto rats (WKY, n=10) were also studied.
At 13 weeks of age, all rats were instrumented with aortic and jugular catheters, and at 14 weeks we measured heart rate reflexes to rapid intravenous infusions of methoxamine (100 μg/kg, cardiac baroreflex) and serotonin (5 to 60 μg/kg, von Bezold-Jarisch cardiac chemosensitive reflex), with either α-rat ANP (150 ng/kg per minute IV) or saline vehicle (270 μL/h IV) infusion.
Perindopril treatment for 6-week (SHR-S) and 9-week (SHR-L) durations maintained blood pressure at normotensive levels in both groups.
SHR-S exhibited a small degree of cardiac hypertrophy (LV/BW was 8% higher than in WKY but 11% less than in untreated SHR), but LV/BW was normalized in SHR-L (to within 1% of WKY LV/BW).
In WKY, ANP significantly (
P
<0.
05) enhanced bradycardic responses to both the cardiac baroreflex (by 42±10%) and von Bezold-Jarisch chemosensitive reflex (by 17±5%) activation but had no effect in SHR.
The cardiac reflex action of ANP was restored in SHR-L (ANP enhanced reflex bradycardia by 28±12% and 36±8%, baroreflex and von Bezold-Jarisch reflex, respectively;
P
<0.
05), but SHR-S, which developed some cardiac hypertrophy, remained unresponsive to ANP.
Our results suggest that the inability of ANP to sensitize cardiac vagal (nonarterial) afferents in SHR was not due to an inherited irreversible component, or the hypertension per se, but was associated with the presence of cardiac hypertrophy.
A functional consequence of hypertension-induced cardiac hypertrophy may be the inhibition of the cardioprotective action of ANP through cardiac vagal reflexes.
Related Results
ANP Enhances Bradycardic Reflexes in Normotensive but Not Spontaneously Hypertensive Rats
ANP Enhances Bradycardic Reflexes in Normotensive but Not Spontaneously Hypertensive Rats
Abstract
Baroreflex control of heart rate in spontaneously hypertensive rats (SHR) is defective, largely because of a poor vagal contribution to the reflex. We have dem...
The Prognostic Role of Atrial Natriuretic Peptides in Hemodialysis Patients
The Prognostic Role of Atrial Natriuretic Peptides in Hemodialysis Patients
<i>Background:</i> It is well known that plasma atrial natriuretic peptide (ANP) is an indicator of extracellular fluid volume expansion and that plasma ANP is consider...
Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats
Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive Rats
AbstractChronic infusion of atrial natriuretic peptide (ANP) has been shown to cause natriuresis, diuresis, and hypotension in rats and humans. We explored the effect of a continuo...
Renal and Hemodialysis Clearances of Endogenous Natriuretic Peptide
Renal and Hemodialysis Clearances of Endogenous Natriuretic Peptide
The purpose of the present study was to assess the plasma levels of atrial natriuretic peptide (ANP) in chronically uremic patients not submitted to dialysis and to determine the p...
ANP receptors in neurons and astrocytes from spontaneously hypertensive rat brain
ANP receptors in neurons and astrocytes from spontaneously hypertensive rat brain
In this study we compared the levels and responsiveness of atrial natriuretic peptide (ANP) receptors in neuronal and astrocyte glial cultures from spontaneously hypertensive (SH) ...
Guanylyl Cyclase Receptors Mediate Cardiopulmonary Vagal Reflex Actions of ANP
Guanylyl Cyclase Receptors Mediate Cardiopulmonary Vagal Reflex Actions of ANP
Atrial natriuretic peptide (ANP) potentiates vagal cardiopulmonary reflexes due to chemosensory (Bezold-Jarisch [B-J] reflex) or mechanosensory (ramp baroreflex) activation. The AN...
Atrial Natriuretic Peptide Gene Delivery Reduces Stroke-Induced Mortality Rate in Dahl Salt-Sensitive Rats
Atrial Natriuretic Peptide Gene Delivery Reduces Stroke-Induced Mortality Rate in Dahl Salt-Sensitive Rats
Abstract
—Atrial natriuretic peptide (ANP) is a powerful hormone with hypotensive, natriuretic, diuretic, and many other beneficial effects. Direct infusion of ANP in t...
Atrial natriuretic peptide and N‐terminal atrial natriuretic peptide in plasma reflect right ventricular volumes following coronary artery surgery
Atrial natriuretic peptide and N‐terminal atrial natriuretic peptide in plasma reflect right ventricular volumes following coronary artery surgery
Background: Atrial natriuretic peptide (ANP) and the more stable N‐terminal fragment (N‐ANP) of prohormone are peptides, released in equimolar amounts from cardiac myocytes in resp...

